The direct offering of shares and warrants by Lexaria Bioscience could lead to dilution of existing shareholders' equity. This is because the introduction of additional shares into the market increases the supply, which could put downward pressure on the stock price in the short term. However, the impact may be offset by the additional capital raised through the offering, which could be used to fund growth initiatives.